Boehringer links up with Thoeris to tackle UCDs

Privately-held German pharma major Boehringer Ingelheim and Austria’s Thoeris have announced a collaboration and license deal aimed at investigating new first-in-class therapies for patients with urea cycle disorders (UCDs).

These rare disorders are diseases caused by genetic liver dysfunctions leading to excess ammonia levels in the blood for which only insufficient treatments exist to date.

Thoeris claims to have developed an approach that could transform the treatment of patients with these conditions. Boehringer will contribute its expertise in drug discovery and development to advance potential medications into the clinic.